Combination of C21 and ARBs with rhACE2 as a therapeutic protocol: A new promising approach for treating ARDS in patients with coronavirus infection

Marzieh Soheili1,2, Kaveh Haji-allahverdipoor3,4, Mohamad Bagher Khadem-erfan1, Babak Baban1, Bahram Nikkhoo1,6, Anwar Eliasi7, Sherko Nasseri*1

Abstract

Background: Coronavirus disease 2019 (COVID-19) is caused by a new severe acute respiratory syndrome Coronavirus. COVID-19 patients are at risk for acute respiratory distress syndrome and death from respiratory failure.

Methods: In this study the complete genome of the SARS-CoV-2 reference sequence, geologically isolated types, and Coronavirus related to human diseases were compared by the Molecular Phylogenetic Maximum Likelihood method. The secondary and tertiary structures of the main protease of SARS-CoV were defined as the most similar viruses to SARS-CoV-2, aligned with chimera software. Therefore, considering ineffective antiviral medications used for SARS-CoV and the importance of preventing acute respiratory distress syndrome as the main cause of mortality, 2 strategies were adopted to acquire the most effective drug combination.

Results: The results of phylogenetic analysis showed that SARS-CoV is the most similar virus to SARS-CoV-2. The secondary structure and superimposing of tertiary structure did not show a significant difference between SARS and SARS-CoV-2 3C-like main protease and the root means square deviation between Cα atoms did not support the difference between the 2 protein structures. Thus, these 2 mechanisms were fostered in accordance with the correlation between acute respiratory distress syndrome-related Coronavirus, angiotensin-converting enzyme 2 on one side and the possible treatments for reducing the respiratory side effects on the other. The analysis of renin-angiotensin system as well as the tested drugs applied to acute respiratory distress syndrome cases, indicated that angiotensin II receptor blockers, angiotensin-converting enzyme inhibitors, and C21 as nonpeptide agonist might possess a promising modality of treatment for acute respiratory distress syndrome. Furthermore, implementing recombinant human ACE2 as a competitive receptor might be an effective way to trap and chelate the SARS-CoV-2 particles.

Conclusion: The data suggest that combination therapy of angiotensin II receptor blockers and C21 could be a potential pharmacologic regimen to control and reduce acute respiratory distress syndrome. Moreover, rhACE2 can be recommended as an effective protective antiviral therapy in the treatment of COVID-19 and its complications.

Keywords: Acute respiratory distress syndrome, SARS-Associated Coronavirus, Renin-Angiotensin system, SARS-CoV-2

Conflict of Interest: None declared

Funding: None

*This work has been published under CC BY-NC-SA 1.0 license.

Copyright© Iran University of Medical Sciences

Cite this article as: Soheili M, Haji-allahverdipoor K, Khadem-erfan MB, Baban B, Nikkhoo B, Eliasi A, Nasseri Sh. Combination of C21 and ARBs with rhACE2 as a therapeutic protocol: A new promising approach for treating ARDS in patients with coronavirus infection. Med J Islam Repub Iran. 2020 (14 Sep);34:120. https://doi.org/10.47176/mjiri.34.120

What is “already known” in this topic:
COVID-19 has become an epidemic and eventually a global pandemic burden worldwide. COVID-19 patients are at risk for acute respiratory distress syndrome and death from respiratory failure. The Coronavirus antiviral treatment had no significant therapeutic or preventive effect and there is no effective treatment strategy to prevent death from COVID-19.

—What this article adds:
This study suggests the combination of C21 and ARBs as an applicable effective therapeutic protocol. Also, rhACE2 acts as a competing molecule for the SARS-CoV-2 receptor, and by binding to SARS-CoV-2, it reduces the binding of the virus to its receptor at the tissue level and can be potentially added to the current treatment protocol as an effective method.
Introduction

The Coronavirus family includes pathogens of many animal species and humans. There are 6 different CoV strains in humans: HCoV-229E (229E), HCoV-OC43(OC43), severe acute respiratory syndrome Coronavirus (SARS-CoV), HCoV NL63 (NL63), HCoV-HKU1 (HKU1), and Middle East respiratory syndrome Coronavirus (MERS-CoV) (1). Coronavirus-19 (SARS-CoV-2) is a novel virus found in Wuhan, China, in December 2019 and can cause respiratory signs and symptoms similar to SARS and MERS (2). It is an enveloped and single-stranded ribonucleic acid having 9-12 nm-long surface spikes. The S protein is one of the 4 major proteins on the envelope binding to the angiotensin-converting enzyme2 (ACE2) receptor for entering the host cell (3, 4). It can be transmitted through human-to-human contacts mainly by respiratory droplets (5). The median time to show the symptoms is 9 days (6). SARS and MERS were epidemics in 2003 and 2014, respectively (7, 8). The evaluation of the SARS-CoV-2 outbreak shows that the virus is more prevalent in men (73%) and has a case fatality ratio (CFR) of 2%. MERS is also common in men (66.6%). Nonetheless, the CFR is much higher than SARS-CoV-2 (35%). Women represented a higher prevalence (55.7%) of SARS with a CFR between 13.2%-22.3% (2).

There is a spectrum of symptoms, mainly nonspecific, from asymptomatic to death (9). Fever, cough, myalgia, fatigue, nausea, diarrhea, and headache are the probable symptoms of CoV (10, 11). The onset may present with rapid progression to shock or acute respiratory distress syndrome (ARDS), acute kidney injury, or acute cardiac injury (5, 12). In blood test assay, patients might have lower blood cell counts (lymphopenia, thrombocytopenia, increased C-reactive protein level, erythrocyte sedimentation rate, lactate dehydrogenase, creatinine, and prolonged prothrombin time) (10, 12-14). Chest radiography cannot be a useful radiological examination in the early stages of infection (15). Chest CT provides a fast, convenient, and appropriate search strategy. We implemented a comprehensive therapeutic modality by adding vasodilatation and antiproliferation therapies to the current antiviral treatment in patients with ARDS-associated Coronavirus.

Methods

Data acquisition and phylogenetic tree draw

The complete genomes of the first main Wuhan nCoV-19 and 43 isolated types of novel SARS-CoV-2 with identical geology were retrieved the novel severe acute respiratory syndrome Coronavirus 2 genome data hub. Also, 12 complete genomes from alpha and beta Coronavirus were derived from the US National Library of Medicine, NCBI database. All the retrieved sequences selected from alpha and beta Coronavirus that cause disease in a comparable fashion. Comparison was done based on homology to find an effective antiviral treatment pattern. Further, we assessed the potential for adopting a more comprehensive therapeutic modality by adding vasodilatation and antiproliferation therapies to the current antiviral treatment in patients with ARDS-associated Coronavirus.

2D and 3D structure alignment

The model structures of the first main like proteinase of the SARS-CoV-2 (6LU7) and the SARS-CoV (1q2w), retrieved by PDB, were taken and analyzed by treating PDB primary structure by filling in missing residues. Also, the alignment of protein sequences, the secondary and tertiary structure between SARS-CoV and SARS-CoV-2 C-like main protease, was done by chimera software. RMSD (root mean square deviation) between Ca atoms was calculated by chimera software and was 0.979.

Search strategy

To retrieve relevant studies, we aimed to choose an appropriate search strategy. We implemented a comprehen-
C21 and ARBs with rhACE2 promising new approach for treating ARDS in coronavirus infection

Table 1. The members of the genus of alpha and beta coronavirus that has greater clinical importance concerning humans are listed based on a host, receptors, pathogenic symptoms, and mortality were shown. No data found in the line areas.

| Virus name                              | Accession Number reference | Source information                  | Proteins encoded | Host                  | receptor | Clinical feature                           | Outbreak mortality /year          |
|-----------------------------------------|-----------------------------|-------------------------------------|------------------|------------------------|----------|--------------------------------------------|-----------------------------------|
| Human Coronavirus HKU1                  | NC_006577                   | Isolate: HKU1                       | 8                | Human                  | O-acetylated sialic acid (52) | Febrile convulsion (53)            | N/A (54)/November 2007 to March 2008 (53) |
| Human coronavirus NL63                  | NC_005831                   | Strain: Amsterdam I                 | 6                | Human                  | ACE2 (55) | Croup (53)                                 | N/A (54)                          |
| Betacoronavirus England 1               | NC_038294                   | Strain: England 1; isolate:H123990006 | 10               | Human, Vertebrates     | --------- | ---------                                  | ---------                          |
| Bovine coronavirus                      | NC_003045                   | Isolate: BCoV-ENT                   | 12               | Human, Vertebrates     | N-acetyl-9-O-acetyleneuraminic (56) | Diarrhea (57)                     | ------/ Winter 2006 (58)            |
| Camel alphacoronavirus                  | NC_028752                   | Isolate: camel/Riyadh/Ry141/ 2015   | 7                | Human, Vertebrates     | --------- | Asymptomatic (59)                         |                                  |
| Human coronavirus 229E                  | NC_002645                   | Strain: 229E                        | 8                | Human, Vertebrates     | Human aminopeptidase N (60)  | Mild respiratory symptoms (mostly common in immunocompromised individuals (57) | N/A (54)/Winter 2008 (53)         |
| Human coronavirus OC43                  | NC_006213                   | Strain: ATCC VR-759; sero-type:OC43 | 8                | Human, Vertebrates     | HLA class I antigen (61)     | Necrotizing entrocolitis and gastroenteritis (62) | N/A (54)/November 2008 to January 2009 (53)/Summer 2003 (64) |
| Infectious bronchitis virus             | NC_001451                   | Strain: Beaudette                   | 10               | Human, Vertebrates     | Sialic acid (64)             | Severe respiratory disease, nephritis (57), reproductive disorders (65) | 20-30% (65)----------- |
| Middle East respiratory syndrome-related coronavirus | NC_019843                   | Strain: HCoV-EMC                    | 11               | Human, Vertebrates     | dipeptidyl peptidase 4(DPP4) (66) | Severe acute respiratory syndrome (57) | 37% (57)/2012 and 2015             |
| Severe acute respiratory syndrome coronoavirus 2 | NC_045512                   | Wuhan-Hu-1                          | 12               | Human, Vertebrates     | ACE2 (67)                     | Severe and Mild respiratory disease (57) | 2-3.4% (68)/2019                  |
| Severe acute respiratory syndrome-related coronavirus | NC_004718                   | Isolate: Tor2                        | 14               | Human, Vertebrates     | ACE2 (69)                     | Severe respiratory disease (70) | 9.5% (70)/2003                     |
| Turkey coronavirus                      | NC_010800                   | Isolate: MG10                       | 11               | Human, Vertebrates     | --------- | Depression, loss of appetite, weight loss, diarrhea, hemorrhage in the jejunum, ileum, cecum (71) | Very low (71)                      |

sive search strategy in PubMed (including Medline), Embase, and Scopus. Our search was mostly focused on the correlation between Coronavirus and ARDS, ACE2 as the main receptor of the virus, and the possible treatments to improve the therapeutic algorithm for reducing the respiratory side effects of this infection. We followed the 3 routes below:

1. The rout correlated with the drugs reduce viral parti-
cle binding to the ACE2.
2. The route related to the medications decrease AT1R.
3. The route defining the drugs increase AT2R.

About 137 papers were retrieved, of which 33 were selected and evaluated. Any signs, symptoms, or treatments which were not correlated with ARDS-related Coronavirus were excluded. We also included review papers, book chapters, and letters to the editor.

Pharmacophore-based virtual screening

In this study, 3D structure of the C21 compound was predicted and minimized using molecular mechanic forcefield “MM+” and quantum mechanic based semi-empirical “AM1” method. Pharmacophore modeling and pharmacophore-based virtual screening were done with Pharmit server (http://pharmit.csb.pitt.edu).

Results

The phylogenetic analysis assessed the complete genome similarity of Wuhan’s main reference sequence of SARS-CoV-2 (NC_045512), other specified geological isolated of SARS-CoV-2, and other alpha and beta Coronaviruses associated with human diseases. The results of the phylogenetic analysis and distance analysis (data not shown) showed that the SARS-CoV is the most similar virus to SARS-CoV-2 (Fig. 1). The 3C-like main protease of SARS-CoV-2 and SARS-CoV, which is in the center of attention for antiviral treatment, was analyzed. The final model, alignment of the protein sequence, and the secondary structure and superimposing of tertiary structure did not show a significant difference between SARS and other viruses.

Fig. 1. Molecular Phylogenetic analysis by the Maximum Likelihood method. The evolutionary history was inferred by using the Maximum Likelihood method based on the Tamura-Nei model (55). The tree with the highest log likelihood (-225915.89) is shown. The percentage of trees in which the associated taxa clustered together is shown next to the branches. Initial tree(s) for the heuristic search were obtained automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated using the Maximum Composite Likelihood (MCL) approach and then selecting the topology with superior log likelihood value. The analysis involved 55 nucleotide sequences. Codon positions included were 1st+2nd+3rd+Noncoding. All positions containing gaps and missing data were eliminated. There were a total of 24218 positions in the final dataset. Evolutionary analyses were conducted in MEGA7 (56).
SARS-CoV-2 3C-like main protease (Fig. 2). Also, the RMSD (root mean square deviation) between Cα atoms was calculated by chimera software and was 0.979, which did not support the difference between the 2 protein structures. The results of our evaluations based on the effective drugs of angiotensin 2 receptors in the RAS signaling pathway showed that angiotensin receptor (ARB) II inhibitors, such as losartan, telmisartan and valsartan, could be effective in limiting AT1R activity. Also, ACE inhibitors, such as captopril, lisinopril, and enalapril, can reduce the production of ANGII and thus prevent AT1R activation. On the other hand, rathinasa-bapathy et al reported C21 treatment on lung fibrosis induced rats (by bleomycin installation) attenuates lung injury. They recommended further evaluations for applying C21 as a promising approach for the clinical treatment of idiopathic pulmonary fibrosis (IPF) and Group III PH (24). The search results based on the strategy to reduce viral particle binding to the ACE2 receptor resulted in finding recombinant human ACE2 (rhACE2) as a potential therapeutic approach in the management of emerging lung distress as avian influenza A infections (25, 26). Pharmacophore-based virtual screening of databases with millions of compounds (ZINC, PubChem, CHEMBL 25, ChemSpace, MCULE, MolPort, and LabNetwork) could not find any compounds that may match with C21. Thus, it can be stated that C21 is a highly selective and specific compound with special structural features having no similar compounds or substitutions (Fig. 3).

Discussion
High similarity between the complete genomes and subsequently homology of 2 main protease protein structures basically should lead to a similar response to therapeutic targeting, especially for antiprotease therapy. On the other hand, SARS-CoV-2 had a rapid rate of spread and transformation from a local epidemic status in Wuhan to a global pandemic situation that has affected more than 100 countries. Also, there is a great concern about the increase in its fatality rate from 2% in developed countries to about 3.5% in developing countries. It can be concluded that antiviral drugs alone could not be effective in reducing
mortality rates due to viral infection. Thus, reducing the clinical symptoms of critically ill patients suffering from acute respiratory distress syndrome due to novel Coronavirus and diminishing the severity and mortality of patients is an urgent problem to be solved clinically.

ARDS is a distinct condition with characterized clinico-pathologic and radiographic findings, involving acute onset and hypoxemia that does not respond to a single effective pharmacological intervention (27, 28). ARDS is the most severe form of acute lung distress and is characterized by pulmonary edema, severe hypoxia, and increased inflammatory cells in the lung tissue (29). SARS-CoV-2 is known as the COVID-19 pathogen demonstrating atypical pneumonia with high fever and severe dyspnea (30). From December 31, 2019 up to now, the world has been experiencing an outbreak of SARS-CoV-2. In our assay, we described the correlation of SARS-CoV-2 with ACE2 in the lung to recommend the best treatment for this infection.

The main receptor of the Coronavirus is ACE2, which is the main factor of the renin-angiotensin system (RAS) in pulmonary and cardiovascular disorders (31, 32). The normal pathway has been shown in Figure 4 A. As it is presented, ACE accelerates producing ANG II from ANG I. Then, ANG II effects are mediated by its receptor angiotensin receptor 1 (AT1R), which leads to activating vasoconstriction and cell proliferation. On the other hand, ACE2 (expressed in vascular endothelial cells of heart, kidneys, testis, and lung) (33) converts AG II to ANG 1-7 to mediate AT2R receptors for activating vasodilation and apoptosis, which can prevent the proliferation of fibroblasts in the lung (29). One of the important pathways which influences related lung disorders, such as cardiovascular disorders, pulmonary hypertension, pulmonary

![Fig. 3. A. Three-dimensional (3D) structure of the C21 compound. B. Pharmacophore model of C21 includes 17 features (white balls indicate hydrogen bond donors, Orange balls indicate hydrogen bond acceptors and Green balls indicate hydrophobic groups)](image-url)
edema, and pulmonary fibrosis, are the diseases related to RAS dysfunction (29). Pulmonary fibrosis is reported as a considerable problem that occurs due to SARS-CoV-2, which is seen in the chest CT scan and is produced through the fibroblasts activated by ANG2 immune-reactivation of lung fibroblasts, macrophages and bronchial and alveolar epithelium (34). These reactions are seen in the chest CT scan as multiple patchy consolidations and ground-glass opacities (GGO) (35). All these pathologies are because of the involvement of RAS in SARS pathogenesis. SARS-CoV-2 is downregulated when it binds to its receptor (ACE2). The downregulation of ACE2 expression leads to ARDS through decreasing AT2R and preventing vasodilatation and fibroblast apoptosis (36). Figure 4 B is representative of this cascade. Kuba et al believe that ACE2 can be applied as a novel drug for controlling ARDS (29). In the case of SARS-CoV-2, there is a tentative suggestion that should be considered to treat ARDS in patients with SARS-CoV-2. Since the pathway of AT1R is amplified by SARS-CoV-2,
angiotensin II receptor blockers (ARBs), such as losartan, telmisartan or valsartan, can reduce the intensity of invasion and mortality of SARS-CoV-2 infection (37). Therefore, increasing ACE2 activity and redirecting the RAS pathway in the direction of the ATII R stimulation might be an effective potential therapy for ARDS related to SARS-CoV-2 (29). Activation of angiotensin II receptors (AT2R) can be a mechanism that leads to vasodilatation, apoptosis, and inhibition of fibroblast cell proliferation in the lung. Therefore, redirection of the RAS system to activate AT2R requires the use of the C21 molecule as the selective and specific agonist of ATII R.

As mentioned above, stimulating the AT2 receptor by C21 can prevent and attenuate the progression of lung fibrosis, infiltration of macrophages in the lungs, lung inflammation, pulmonary collagen accumulation, and muscularization of the pulmonary vessels. C21 as a highly selective non-peptide agonist of AT2Rs (38-41) has an oral bioavailability of 20% to 30% and an estimated half-life of 4 hours in plasma (42). Administration of C21 in various cardiovascular disease models, including the postmyocardial infarction Wistar rat, the stroke-prone hypertensive rat, and the 2-kidney, and 1-clip hypertensive Sprague-Dawley (SD) rat (43-46), resulted in beneficial organ-protective effects. Also, Menk et al reported Direct AT2 receptor stimulation with C21 led to significant inhibition of tumor necrosis factor-alpha and IL-6 expressions in the lungs; and a rodent model of acute lung injury and stimulation of the AT2 receptor with the direct agonist Compound 21 (C21) might have a beneficial effect on pulmonary inflammation and might improve pulmonary gas exchange (12). Rathinasabapathy et al reported C21 treatment improved pulmonary pressure, reduced muscularization of the pulmonary vessels, and normalized cardiac function in male Sprague Dawley rats with induced lung fibrosis (24). However, a potential antihypertensive effect of C21 manifests itself invivo when the RAS pathway redirected to activation of AT2R because in physiological status, AT1R is predominant. Thus, to observe the effects resulting from AT2R stimulation, it may be necessary to block AT1R when combined with a low-dose ARB that does not modify the normal blood pressure; C21 exerts an antihypertensive action (47). Also, the ACE inhibitors mediate decreasing the conversion of ANGII to ANGI. An experimental model of acute lung injury (ALI) has proved that captopril can reduce pulmonary injury by protecting the vascular endothelium (33). Many ACE inhibitors are applied to treating hypertension and cardiovascular diseases. In this group of drugs, Captopril, Lisinopril, Enalapril, Ramipril, Perindopril, Benazepril, and Moxepiril are known. Although the target of these drugs is ACE, due to the high similarity between the protein and structural sequences of ACE and ACE2, these drugs can affect both pathways (ACE and ACE2) (51).

The effect area of the proposed drugs on the RAS pathway is shown in the Figure 4 C.

The SARS-CoV-2 virus particles interact strongly with ACE2 through its S protein for its entry into the host cell (48). Therefore, antibodies and small molecular inhibitors that can block the interaction between ACE2 with receptor-binding domain (RBD) of SARS-CoV-2 S protein should be considered as the main part of the treatment (49). There is also a potential strategy to prevent ACE2 binding to SARS-CoV-2, which is a recombinant human ACE2 (rhACE2) as a competitive receptor for chelating the SARS-CoV-2 virus particles (31, 32). The use of Ang II receptor blockers or ACE inhibitors has been effective in decreasing lung injury in animal models, but it might lead to systemic hypotension as a potential side effect. Since ACE2 protects the lungs from developing ARDS through dominating the AT2R in comparing with AT1R and redirecting the RAS pathway to promote the vasodilatation and apoptosis for the severe acute respiratory syndrome (50), the recombinant ACE2 protein may have an important role in protecting ARDS as a mimicry Coronavirus receptor and also as a potential therapeutic approach in the management of emerging lung diseases (25, 26).

According to the pathway blocked by ACEIs, in which angiotensin II is reduced, it is preferred not to apply this group of drugs, because angiotensin II should be available in the system for producing Angiotensin 1-7. The competition with the binding of SARS-CoV-2 with rhACE2 seems to effectively prevent its entrance into the host cell with chelating viral particles.

Conclusion
According to the mechanism of action and the signaling pathway of Coronavirus which affects the Renin-Angiotensin system, we suggest the combination of C21 and ARBs as an applicable effective therapeutic protocol as well as rhACE2 as a preventing competitive molecule, which ablates the adhesion of the SARS-CoV-2 and may be an effective additional modality for the current therapeutic protocol, having all other medical considerations based on individual requirements.

Conflict of Interests
The authors declare that they have no competing interests.

References
1. Kin N, Misseczak F, Lin W, Gouilh MA, Vabret AJV. Genomic analysis of 15 human coronaviruses OC43 (HCoV-OC43s) circulating in France from 2001 to 2013 reveals a high intra-specific diversity with new recombinant genotypes. Viruses. 2015;7(5):2358-77.
2. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Babi S, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol. 2020.
3. Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus Disease 2019 (COVID-19): A Perspective from China. Radiology. 2020;200490.
4. Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microb Cell Mol Biol Rev. 2005;69(4):635-64.
5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
6. The Lancet. Emerging understandings of 2019-nCoV. Lancet. 2020;395(10221):311.
7. Mackay IM, Arden KE. MERS coronavirus: diagnostics, epidemiology and transmission. Virol J. 2015;12(1):222.
8. Donnelly CA, Ghani AC, Leung GM, Hedley AJ, Fraser C, Riley S, et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome. Cambridge. 2003;18(10):1337-48.

http://mjirimi.uums.ac.ir
Med J Islam Repub Iran. 2020 (14 Sep); 34.120.
11. W. Gu et al. (2020). "Epidemiological and clinical characteristics of 2019 novel coronavirus pneumonia.” Lancet 2020;395(10223):1545-2023.

12. D. Wang et al. (2020). "Clinical characteristics of 1242 COVID-19 patients in Wuhan, China.” JAMA Intern Med 2020;180(7):982-988.

13. F. Guan et al. (2020). "Clinical characteristics of 1916 patients with 2019 novel coronavirus pneumonia in Wuhan, China.” Lancet 2020;395(10223):1794-1803.

14. S. Su et al. (2020). "Widespread imaging features of COVID-19: a single-centre, retrospective, observational study.” Radiology 2020;295(2):759-767.

15. M. Ng et al. (2020). "Epidemiology and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia.” J Med Virol 2020;92(5):571-578.

16. N. Chen et al. (2020). "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia.” J Med Virol 2020;92(5):545-552.

17. B. Udugama et al. (2020). "Epidemiological and clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

18. K. Guan et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

19. S. Wu et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

20. G. Zhang et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

21. S. Wang et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

22. W. Liu et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

23. K. Huang et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

24. J. Wang et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

25. X. Zhou et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

26. Y. Yang et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

27. J. Wu et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

28. F. Guan et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

29. Z. Zhang et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

30. L. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

31. J. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

32. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

33. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

34. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

35. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

36. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

37. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

38. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

39. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

40. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

41. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

42. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

43. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

44. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

45. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

46. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

47. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

48. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

49. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

50. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

51. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

52. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

53. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

54. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.

55. Y. Song et al. (2020). "Clinical characteristics of 2019 novel coronavirus infection in China.” N Engl J Med 2020;382(20):1968-1977.
57. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020.
58. Decaro N, Mari V, Desaro C, Campolo M, Elia G, Martella V, et al. Severe outbreak of bovine coronavirus infection in dairy cattle during the warmer season. Vet Microbiol. 2008;126(1-3):30-9.
59. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020.
60. Yeager CL, Ashman RA, Williams RK, Cardellichio CB, Shapiro LH, Look AT, et al. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature. 1992;357(6377):420-2.
61. Collins A. HLA class I antigen serves as a receptor for human coronavirus OC43. Immunol Invest. 1993;22(2):95-103.
62. Leung TF, Li CY, Lam WY, Wong GW, Cheuk E, Ip M, et al. Epidemiology and clinical presentations of human coronavirus NL63 infections in hong kong children. J Clin Microbiol. 2009;47(11):3486-92.
63. Patrick DM, Petric M, Skowronska DM, Guasparini R, Booth TF, Krajden M, et al. An Outbreak of Human Coronavirus OC43 Infection and Serological Cross-reactivity with SARS Coronavirus. Can J Infect Dis Med Microbiol. 2006;17(6):330-6.
64. Winter C, Schwegmann-Weiβels C, Cavanagh D, Neumann U, Herrler GJovg. Sialic acid is a receptor determinant for infection of cells by avian Infectious bronchitis virus. J Gen Virol. 2006;87(5):1209-16.
65. Ignjatovic J, Sapats S. Avian infectious bronchitis virus. Rev Sci Tech. 2000;19(2):493-501.
66. Bleibtreu A, Bertine M, Bertin C, Houhou-Fidouh N, Visseaux BJMeni. Focus on Middle East respiratory syndrome coronavirus (MERS-CoV). Med Mal Infect. 2019.
67. Gao QY, Chen YX, Fang J. 2019 novel coronavirus infection and gastrointestinal tract. J Dig Dis. 2020.
68. Organization WH. WHO Director-General's opening remarks at the media briefing on COVID-19 - 3 March 2020.
69. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450-4.
70. Ströher U, DiCaro A, Li Y, Strong JE, Aoki F, Plummer F, et al. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-α. J Infect Dis. 2004;189(7):1164-7.
71. Wege H, Ter Meulen V. The biology and pathogenesis of coronaviruses. Current topics in microbiology and immunology: Springer; 1982. p. 165-200.